Analysis of prostate and seminal vesicle motion: Implications for treatment planning

Beard, Clair J.; Kijewski, Peter K.; Bussière, Marc R.; Gelman, Rebecca; Gladstone, David J.; Shaffer, Kitt; Plunkett, Marianne; Costello, Philip; Coleman, C.N.

doi:10.1016/0360-3016(95)02081-0

Cited by 230 publications

(111 citation statements)

References 7 publications

Supporting

Mentioning

108

Contrasting

Order By: Relevance

“…2 and 3) is in agreement with the presence of internal organ motion in these areas reported in the literature, see e.g. Beard et al [4] and van Herk et al [27].…”

Section: Gas Pockets and Organ Motionsupporting

confidence: 81%

In vivo dosimetry for prostate cancer patients using an electronic portal imaging device (EPID); demonstration of internal organ motion

Kroonwijk

Pasma

Quint

et al. 1998

Radiotherapy and Oncology

View full text Add to dashboard Cite

Purpose: To investigate the use of a commercially available video-based EPID for in vivo dosimetry during treatment of prostate cancer patients.Methods: For 10 prostate cancer patients, the inter-fraction variation within measured portal dose images (PDIs) was assessed and measured PDIs were compared with corresponding predicted PDIs based on the planning CT scan of the patient.Results: For the lateral ®elds, the average standard deviation in the measured on-axis portal doses during the course of a treatment was 0.9%; for the anterior ®elds this standard deviation was 2.2%. The difference between the average on-axis measured portal dose and the predicted portal dose was 0:3^2:1% (1 SD) for the lateral ®elds and 0:7^3:4% (1 SD) for the anterior ®elds. Off-axis differences between measured and predicted portal doses were regularly much larger (up to 15%) and were caused by frequently occurring gas pockets inside the rectum of the patients during treatment or during acquisition of the planning CT scan. The detected gas pockets did sometimes extend into the gross tumour volume (GTV) area as outlined in the planning CT scans, implying a shift of the anterior rectum wall and prostate in the anterior direction (internal organ motion).Conclusions: The developed procedures for measurement and prediction of PDIs allow accurate dosimetric quality control of the treatment of prostate cancer patients. Comparing measured PDIs with predicted PDIs can reveal internal organ motion. q

show abstract

“…2 and 3) is in agreement with the presence of internal organ motion in these areas reported in the literature, see e.g. Beard et al [4] and van Herk et al [27].…”

Section: Gas Pockets and Organ Motionsupporting

confidence: 81%

In vivo dosimetry for prostate cancer patients using an electronic portal imaging device (EPID); demonstration of internal organ motion

Kroonwijk

Pasma

Quint

et al. 1998

Radiotherapy and Oncology

View full text Add to dashboard Cite

show abstract

“…Capsular invasion cannot be differentiated in current PET/CT systems, due to the limited intrinsic spatial resolution of ≈ 4 mm. Potential movement artefacts [13] occurring between CT and PET acquisition furthermore obviate the possibility of evaluating capsular invasion in PET/CT images.…”

mentioning

confidence: 99%

¹¹C‐Choline positron‐emission tomography/computed tomography and transrectal ultrasonography for staging localized prostate cancer

et al. 2007

View full text Add to dashboard Cite

extracapsular extension (ECE), seminal vesicle invasion (SVI) and bladder neck invasion (BNI).The results were compared with the histopathological findings after RP. RESULTSAt pathology, 32 patients were classified pT2, 16 as pT3a and three had pT3b lesions. In four patients the histopathological examination showed pT4 with BNI. The overall accuracy of PET in defining local tumour stage (pT2 and pT3a − 4) was 70%; the overall accuracy by TRUS was 26%. PET was more sensitive than TRUS for detecting ECE (pT3a) and SVI (pT3b) in advanced stages, and in pT4 stages. The sensitivity and positive predictive value (PPV) (95% confidence interval) in stages pT3a-pT4 for PET were 36 (17-59)% and 73 (39-89)%. The sensitivity and PPV in stages pT3a-pT4 for TRUS were 14 (3-35)% and 100 (29-100)%. CONCLUSIONS 11C-choline PET and TRUS tended to understage prostate cancer. This series shows the current limited value of TRUS and PET for making treatment decisions in patients with clinically localized prostate cancer, especially if a nerve-sparing RP is considered. Treatment decisions should not be based on TRUS and 11 C-choline PET findings alone. In future studies, the combination of metabolic and anatomical information of PET and endorectal magnetic resonance imaging should be evaluated, as this might optimize the preoperative staging in prostate cancer.

show abstract

“…Based on the established prostate motion pattern [12][13][14], we created a pool of plans to compensate for prostate movements of 0.5 cm and 1.0 cm in the posterior and superior directions. The shifted prostate contours were created using an in-house program that read in the coordinates of the original prostate contours and shifted the coordinates of the contour to the presumed positions.…”

Section: Materials and Methods A Multiple Adaptive Plan Strategymentioning

confidence: 99%

“…However, this concurrent treatment of the prostate and the pelvic lymph nodes poses a new technical challenge due to the independent movement of the prostate and the pelvic lymph nodes, Movement of the prostate has been well documented [12]. It varies from a few millimeters up to 1.5 cm in relative to the pelvic bones [13,14]. The pelvic lymph nodes, on the contrary, are relatively fixed in close proximity to vascular structures [6], which are presumably fixed with respect to bony anatomy [15].…”

Section: Introductionmentioning

confidence: 99%

Multiadaptive Plan (MAP) IMRT to Accommodate Independent Movement of the Prostate and Pelvic Lymph Nodes

Xia¹

2009

View full text Add to dashboard Cite

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.

show abstract

Analysis of prostate and seminal vesicle motion: Implications for treatment planning

Cited by 230 publications

References 7 publications

In vivo dosimetry for prostate cancer patients using an electronic portal imaging device (EPID); demonstration of internal organ motion

In vivo dosimetry for prostate cancer patients using an electronic portal imaging device (EPID); demonstration of internal organ motion

¹¹C‐Choline positron‐emission tomography/computed tomography and transrectal ultrasonography for staging localized prostate cancer

Multiadaptive Plan (MAP) IMRT to Accommodate Independent Movement of the Prostate and Pelvic Lymph Nodes

Contact Info

Product

Resources

About

Analysis of prostate and seminal vesicle motion: Implications for treatment planning

Cited by 230 publications

References 7 publications

In vivo dosimetry for prostate cancer patients using an electronic portal imaging device (EPID); demonstration of internal organ motion

In vivo dosimetry for prostate cancer patients using an electronic portal imaging device (EPID); demonstration of internal organ motion

11C‐Choline positron‐emission tomography/computed tomography and transrectal ultrasonography for staging localized prostate cancer

Multiadaptive Plan (MAP) IMRT to Accommodate Independent Movement of the Prostate and Pelvic Lymph Nodes

Contact Info

Product

Resources

About

¹¹C‐Choline positron‐emission tomography/computed tomography and transrectal ultrasonography for staging localized prostate cancer